In-vitro anti-tumor activity studies of bridged and unbridged benzyl-substituted titanocenes

Anti-Cancer Drugs

Volumn 16, Issue 10, 2005, Pages 1091-1098

  Kelter, Gerhard ^a   Sweeney, Nigel J ^b   Strohfeldt, Katja ^b   Fiebig, Heinz Herbert ^a   Tacke, Matthias ^b  

^a CHARLES RIVER LABORATORIES   (United States)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

Anti cancer drug; Cisplatin; Human tumor cell lines; Renal cell cancer; Titanocene

Indexed keywords

[1,2 BIS(CYCLOPENTADIENYL) 1,2 BIS(3 DIMETHOXYPHENYL)ETHANEDIYL]TITANOCENE DICHLORIDE; [1,2 BIS(CYCLOPENTADIENYL) 1,2 BIS(4 N,N DIMETHYLAMINOPHENYL)ETHANEDIYL]TITANOCENE DICHLORIDE; BIS[(4 METHOXYBENZYL)CYCLOPENTADIENYL]TITANOCENE DICHLORIDE; CISPLATIN; TITANOCENE DICHLORIDE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG STRUCTURE; HUMAN; HUMAN CELL; IC 50; KIDNEY CARCINOMA; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; TUMOR CELL; UTERUS CANCER;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; INHIBITORY CONCENTRATION 50; NEOPLASMS; ORGANOMETALLIC COMPOUNDS;

EID: 27644514186     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200511000-00008     Document Type: Article

References (30)

1. Gelasco A, Lippard SJ. Anticancer activity of cisplatin and related complexes. Topics Biol Inorg Chem 1999; 1:1-43.
2. Jamieson ER, Lippard SJ. Structure, recognition, and processing of cisplatin-DNA adducts. Chem Rev 1999; 99:2467-2498.
3. Farrell N, Qu Y, Roberts JD. Chemistry and biology of multifunctional DNA binding agents. Topics Biol Inorg Chem 1999; 1:99-115.
4. Köpf-Maier P, Köpf H. Non-platinum group metal antitumor agents. History, current status, and perspectives. Chem Rev 1987; 87:1137-1152.
5. Köpf-Maier P, Köpf H. Transition and main-group metal cyclopentadienyl complexes: preclinical studies on a series of antitumor agents of different structural type. Struct Bonding 1988; 70:103-194.
6. Lummen G, Sperling H, Luboldt H, Otto T, Rubben H. Phase II trial of titanocene dichloride in advanced renal-cell carcinoma. Cancer Chemother Pharmacol 1998; 42:415-417.
7. Kröger N, Kleeberg UR, Mross KB, Edler L, Saß G, Hossfeld DK. Phase II clinical trial of titanocene dichloride in patients with metastatic breast cancer. Onkologie 2000; 23:60-62.
8. 2 and implications for anticancer activity. Metal-Based Drugs 1998; 5:207-215.
9. Allen OR, Croll L, Gott AL, Knox RJ, McGowan PC. Functionalized cyclopentadienyl titanium organometallic compounds as new antitumor drugs. Organometallics 2004; 23:288-292.
10. Boyles JR, Baird MC, Campling BG, Jain N. Enhanced anti-cancer activities of some derivatives of titanocene dichloride. J Inorg Biochem 2001; 84:159-162.
11. Causey PW, Baird MC. Synthesis, characterization, and assessment of cytotoxic properties of a series of titanocene dichloride derivatives. Organometallics 2004; 23:4486-4494.
12. Meyer R, Brink S, van Rensburg CEJ, Joone GK, Görls H, Lotz S. Synthesis, characterization and antitumor properties of titanocene derivatives with thiophene containing ligands. J Organomet Chem 2005; 690:117-125.
13. 2). J Organomet Chem 1997; 545/546:105-110.
14. Hartl F, Cuffe L, Dunne JP, Fox S, Mahabiersing T, Tacke M. Reduction of substituted fulvenes studied by spectro-electrochemistry and ab initio theory. J Mol Struct 2001; 559:331-339.
15. 5. J Mol Struct 2001; 570:197-202.
16. Fox S, Dunne JP, Dronskowski D, Schmitz D, Tacke M. Synthesis and structural characterisation of a novel chiral ansa-cobaltocenium hexafluorophosphate. Eur J Inorg Chem 2002; 11:3039-3046.
17. Eisch JJ, Xian S, Owuor FA. Novel synthesis of ansa-metallocenes via the reductive dimerization of fulvenes with group 4 metal divalent halides. Organometallics 1998; 17:5219-5221.
18. Eisch JJ, Owuor FA, Xian S. Novel synthesis of unbridged, sterically substituted zirconocene dichlorides from fulvenes and dialkylzirconium dichlorides via zirconium(IV) hydride transfer. Organometallics 1999; 18:1583-1585.
19. 2. Organometallics 1997; 16:4567-4571.
20. Fox S, Dunne JP, Tacke M, Gallagher JF. Novel derivatives of ansatitanocenes procured from 6-phenylfulvene: a combined experimental and theoretical study. Inorg Chim Acta 2004; 357:225-234.
21. Tacke M, Allen LT, Cuffe LP, Gallagher WM, Lou Y, Mendoza O, et al. Novel Titanocene anti-cancer drugs derived from fulvenes and titanium dichloride. J Organomet Chem 2004; 689:2242-2249.
22. Rehmann FJK, Cuffe LP, Mendoza O, Rai DK, Sweeney N, Strohfeldt K, et al. Heteroaryl substituted ansa-titanocene anti-cancer drugs derived from fulvenes and titanium dichloride. Appl Organomet Chem 2005; 19:293-300.
23. Tacke M, Cuffe LP, Gallagher WM, Lou Y, Mendoza O, Müller-Bunz H, et al. Methoxy-phenyl substituted ansa-titanocenes as potential anti-cancer drugs derived from fulvenes and titanium dichloride. J Inorg Biochem 2004; 98:1987-1994.
24. Rehmann FJK, Rous AJ, Mendoza O, Pampillon C, Strohfeldt K, Sweeney N, et al. Novel substituted ansa-titanocene anti-cancer drugs. Polyhedron 2005; 24:1250-1255.
25. Sweeney N, Mendoza O, Müller-Bunz H, Pampillon C, Rehmann F-KJ, Strohfeldt K, et al. Novel benzyl substituted titanocene anti-cancer drugs. J Organomet Chem 2005; in press.
26. Roth T, Burger AM, Dengler WA, Willmann H, Fiebig HH. Human tumor cell lines demonstrating the characteristics of patient tumors as useful models for anticancer drug screening. Contrib Oncol 1999; 54:145-156.
27. Fiebig HH, Berger DP, Dengler WA, Wallbrecher E, Winterhalter BR. Combined in vitro/in vivo test procedure with human tumor xenografts. Contrib Oncol 1992; 42:321-351.
28. Dengler WA, Schulte J, Berger DP, Mertelsmann R, Fiebig HH. Development of a propidium iodide fluorescence assay for proliferation and cytotoxicity assays. Anticancer Drugs 1995; 6:522-532.
29. Fiebig HH, Dengler WA, Roth T. Human tumor xenografts: predictivity, characterization, and discovery of new anticancer agents. Contrib Oncol 1999; 54:29-50.
30. Roth T, Burger AM, Dengler WA, Willmann H, Fiebig HH. Human tumor cell lines demonstrating the characteristics of patient tumors as useful models for anticancer drug screening. Contrib Oncol 1999; 54:145-156.